<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7493771\results\search\disease\results.xml">
  <result pre="Living with HIV Clinical characteristics, risk factors, and incidence of" exact="symptomatic" post="coronavirus disease 2019 in a large cohort of adults"/>
  <result pre="HIV Clinical characteristics, risk factors, and incidence of symptomatic coronavirus" exact="disease" post="2019 in a large cohort of adults living with"/>
  <result pre="[a], [b], [c], Correspondence to Jose L. Blanco, MD, PhD," exact="Infectious" post="Disease Department, Hospital Clinic de Barcelona-Institut dâ€™Investigacions BiomÃ¨diques August"/>
  <result pre="[b], [c], Correspondence to Jose L. Blanco, MD, PhD, Infectious" exact="Disease" post="Department, Hospital Clinic de Barcelona-Institut dâ€™Investigacions BiomÃ¨diques August Pi"/>
  <result pre="PMC and Europe PMC, consistent with existing copyright protections.aids-34-1775.pdf Supplemental" exact="Digital" post="Content is available in the text Abstract Background: It"/>
  <result pre="is unclear how characteristics, risk factors, and incidence of coronavirus" exact="disease" post="2019 (COVID-19) in people living with HIV (PLWH) differ"/>
  <result pre="the general population. Methods: Prospective observational single-center cohort study of" exact="adult" post="PLWH reporting symptoms of COVID-19. We assessed clinical characteristics,"/>
  <result pre="any HIV-related or antiretroviral-related factor. COVID-19 standardized incidence rate was" exact="lower" post="in PLWH than in the general population. These findings"/>
  <result pre="should be confirmed in larger multicenter cohort studies. Keywords coronavirus" exact="disease" post="2019 HIV prospective observational trial severe acute respiratory syndrome"/>
  <result pre="studies. Keywords coronavirus disease 2019 HIV prospective observational trial severe" exact="acute" post="respiratory syndrome coronavirus 2 Introduction Risk for severe coronavirus"/>
  <result pre="Keywords coronavirus disease 2019 HIV prospective observational trial severe acute" exact="respiratory" post="syndrome coronavirus 2 Introduction Risk for severe coronavirus disease"/>
  <result pre="coronavirus disease 2019 HIV prospective observational trial severe acute respiratory" exact="syndrome" post="coronavirus 2 Introduction Risk for severe coronavirus disease 2019"/>
  <result pre="acute respiratory syndrome coronavirus 2 Introduction Risk for severe coronavirus" exact="disease" post="2019 (COVID-19) increases with age, male sex, and comorbidities"/>
  <result pre="[4], there is no clear evidence for a higher COVID-19" exact="infection" post="rate or different disease course in people living with"/>
  <result pre="clear evidence for a higher COVID-19 infection rate or different" exact="disease" post="course in people living with HIV (PLWH) than in"/>
  <result pre="therapy was suggested as a protective factor during the severe" exact="acute" post="respiratory syndrome epidemic in 2003 [17]. Some antiretroviral agents"/>
  <result pre="was suggested as a protective factor during the severe acute" exact="respiratory" post="syndrome epidemic in 2003 [17]. Some antiretroviral agents such"/>
  <result pre="suggested as a protective factor during the severe acute respiratory" exact="syndrome" post="epidemic in 2003 [17]. Some antiretroviral agents such as"/>
  <result pre="transcriptase inhibitors used as anti-HIV therapy may inhibit the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase [18,19]."/>
  <result pre="inhibitors used as anti-HIV therapy may inhibit the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase [18,19]. Moreover,"/>
  <result pre="used as anti-HIV therapy may inhibit the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase [18,19]. Moreover, the"/>
  <result pre="RNA polymerase [18,19]. Moreover, the persistent immune dysregulation that accompanies" exact="HIV infection" post="despite effective antiretroviral therapy could play a role in"/>
  <result pre="polymerase [18,19]. Moreover, the persistent immune dysregulation that accompanies HIV" exact="infection" post="despite effective antiretroviral therapy could play a role in"/>
  <result pre="hospital COVID-19 Standard Operating Procedure (SOP), criteria for admission included" exact="respiratory" post="rate more than 20â€Šbpm, room air oxygen saturation less"/>
  <result pre="including ICU admission. SARS-CoV-2, influenza A and B, and syncytial" exact="respiratory" post="virus were assessed in nasal and pharyngeal swabs by"/>
  <result pre="COVID-19 cases were defined according to the European Centre for" exact="Disease" post="Prevention and Control (ECDC) Case Definition for COVID-19 [25]."/>
  <result pre="degree of severity of COVID-19 was defined according to the" exact="American" post="Thoracic Society guidelines for community-acquired pneumonia [26]. Last CD4+"/>
  <result pre="of severity of COVID-19 was defined according to the American" exact="Thoracic" post="Society guidelines for community-acquired pneumonia [26]. Last CD4+ T-cell"/>
  <result pre="defined according to the American Thoracic Society guidelines for community-acquired" exact="pneumonia" post="[26]. Last CD4+ T-cell count and plasma HIV RNA"/>
  <result pre="Results People living with HIV with symptoms suggestive of coronavirus" exact="disease" post="2019 By 10 May 2020, 62 PLWH out of"/>
  <result pre="patients tested negative for SARS-CoV-2 RT-PCR and alternative causes were:" exact="pneumococcal pneumonia" post="(nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2), urinary tract infection (nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1),"/>
  <result pre="tested negative for SARS-CoV-2 RT-PCR and alternative causes were: pneumococcal" exact="pneumonia" post="(nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2), urinary tract infection (nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1),"/>
  <result pre="for SARS-CoV-2 RT-PCR and alternative causes were: pneumococcal pneumonia (nâ€Š=â€Š2)," exact="syphilis" post="(nâ€Š=â€Š2), urinary tract infection (nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1), acute tonsillitis"/>
  <result pre="RT-PCR and alternative causes were: pneumococcal pneumonia (nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2)," exact="urinary tract infection" post="(nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1), acute tonsillitis (nâ€Š=â€Š1), and diabetic ketoacidosis"/>
  <result pre="alternative causes were: pneumococcal pneumonia (nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2), urinary tract" exact="infection" post="(nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1), acute tonsillitis (nâ€Š=â€Š1), and diabetic ketoacidosis"/>
  <result pre="were: pneumococcal pneumonia (nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2), urinary tract infection (nâ€Š=â€Š2)," exact="tuberculosis" post="(nâ€Š=â€Š1), acute tonsillitis (nâ€Š=â€Š1), and diabetic ketoacidosis (nâ€Š=â€Š1). COVID-19"/>
  <result pre="pneumonia (nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2), urinary tract infection (nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1)," exact="acute" post="tonsillitis (nâ€Š=â€Š1), and diabetic ketoacidosis (nâ€Š=â€Š1). COVID-19 was confirmed"/>
  <result pre="(nâ€Š=â€Š2), syphilis (nâ€Š=â€Š2), urinary tract infection (nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1), acute" exact="tonsillitis" post="(nâ€Š=â€Š1), and diabetic ketoacidosis (nâ€Š=â€Š1). COVID-19 was confirmed in"/>
  <result pre="urinary tract infection (nâ€Š=â€Š2), tuberculosis (nâ€Š=â€Š1), acute tonsillitis (nâ€Š=â€Š1), and" exact="diabetic ketoacidosis" post="(nâ€Š=â€Š1). COVID-19 was confirmed in 42 cases and probable"/>
  <result pre="in 42 cases and probable in 11 cases. No other" exact="viral" post="respiratory infections concomitant to SARS-CoV-2 were found. Clinical characteristics"/>
  <result pre="42 cases and probable in 11 cases. No other viral" exact="respiratory" post="infections concomitant to SARS-CoV-2 were found. Clinical characteristics of"/>
  <result pre="cases and probable in 11 cases. No other viral respiratory" exact="infections" post="concomitant to SARS-CoV-2 were found. Clinical characteristics of coronavirus"/>
  <result pre="infections concomitant to SARS-CoV-2 were found. Clinical characteristics of coronavirus" exact="disease" post="2019 people living with HIV and outcome Characteristics of"/>
  <result pre="35 (66%) a tenofovir-containing regimen. Table 1 Characteristics of coronavirus" exact="disease" post="2019 patients. The median (IQR) time from the onset"/>
  <result pre="while gastrointestinal symptoms including nausea or vomiting (nâ€Š=â€Š4, 8%) or" exact="diarrhea" post="(nâ€Š=â€Š16, 31%) were rare. Of 38 (72%) patients with"/>
  <result pre="(nâ€Š=â€Š16, 31%) were rare. Of 38 (72%) patients with a" exact="chest" post="radiograph at admission, 26 (70%) had bilateral involvement (nâ€Š=â€Š18,"/>
  <result pre="patients with a chest radiograph at admission, 26 (70%) had" exact="bilateral" post="involvement (nâ€Š=â€Š18, 69%) or interstitial pattern in (nâ€Š=â€Š12, 43%)"/>
  <result pre="three drugs. Two (8%) individuals also received IFN-1Î², seven (28%)" exact="systemic" post="glucocorticoids, or eight (32%) tociluzimab. Mechanical ventilation was used"/>
  <result pre="associated with severity among people living with HIV with coronavirus" exact="disease" post="2019 There were six (11%) severe COVID-19 cases. They"/>
  <result pre="commonly headache (nâ€Š=â€Š0, 0% vs. nâ€Š=â€Š28, 64%; Pâ€Š=â€Š0.0047) at presentation," exact="lower" post="median (IQR) O2 saturation (93% (93â€&quot;96) vs. 98% (96â€&quot;99);"/>
  <result pre="median (IQR) O2 saturation (93% (93â€&quot;96) vs. 98% (96â€&quot;99); Pâ€Š=â€Š0.0121)," exact="lower" post="median (IQR) platelets [135 (80â€&quot;163â€&quot;13.04) vs. 5.93 (4.10â€&quot;7.29)â€ŠÃ—â€Š109/l; Pâ€Š=â€Š0.0489],"/>
  <result pre="factors significantly associated with COVID-19 severity. Factors associated with coronavirus" exact="disease" post="2019 in the people living with HIV cohort We"/>
  <result pre="PLWH (Table 2). Table 2 Factors associated with severe coronavirus" exact="disease" post="2019 in the Hospital Clinic Barcelona people living with"/>
  <result pre="Clinic Barcelona people living with HIV cohort. Incidence of coronavirus" exact="disease" post="2019 in the people living with HIV cohort compared"/>
  <result pre="living with HIV cohort compared with the incidence of coronavirus" exact="disease" post="2019 in the city of Barcelona The standardized incidence"/>
  <result pre="assessing clinical characteristics and outcome, risk factors, and incidence of" exact="symptomatic" post="COVID-19 in a large cohort of PLWH. During the"/>
  <result pre="already described in the general population [1,3,11,12,23,29,30]. However, cough, fever," exact="bilateral" post="lung infiltrates, and lymphocytopenia should prompt differential diagnosis with"/>
  <result pre="suggest that HIV characteristics including CD4+, CD4+/CD8+ ratio, or plasma" exact="viral" post="load, or the type of antiretroviral therapy do not"/>
  <result pre="of COVID-19 seen in this cohort of PLWH was much" exact="lower" post="than that of the general population adjusted by age"/>
  <result pre="should be subject of further research. The current study is" exact="limited" post="by the low number of PLWH diagnosed with symptomatic"/>
  <result pre="is limited by the low number of PLWH diagnosed with" exact="symptomatic" post="COVID-19. Only symptomatic PLWH were included in this study,"/>
  <result pre="the low number of PLWH diagnosed with symptomatic COVID-19. Only" exact="symptomatic" post="PLWH were included in this study, but we now"/>
  <result pre="in PLWH had similar clinical characteristics and outcome but a" exact="lower" post="incidence than in the general population. We were unable"/>
  <result pre="interest There are no conflicts of interest. Supplementary Material Supplemental" exact="Digital" post="Content LINK Supplementary Material Supplemental Digital Content LINK âˆ—Josep"/>
  <result pre="interest. Supplementary Material Supplemental Digital Content LINK Supplementary Material Supplemental" exact="Digital" post="Content LINK âˆ—Josep M. Miro, Esteban Martinez, and Jose"/>
  <result pre="Supplementary Appendix 2. References References 1.GuanW-JNiZ-YHuYLiangW-HOuC-QHeJ-Xet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med2020; 382:17081720.32109013 2.YangJZhengYGouXPuKChenZGuoQet"/>
  <result pre="Lancet HIV2020; 7:e314e316.32304642 6.HÃ¤rterGSpinnerCDRoiderJBickelMKrznaricIGrunwaldSet al.COVID-19 in people living with human" exact="immunodeficiency" post="virus: a case series of 33 patients. Infection2020; 16."/>
  <result pre="of print].31919762 7.WuQChenTZhangHRecovery from COVID-19 in two patients with coexisted" exact="HIV infection." post="J Med Virol2020; 10.1002. 8.Karmen-TuohySCarlucciPMZacharioudakisIMZervouFNRebickGKleinEet al.Outcomes among HIV-positive patients"/>
  <result pre="coexisted HIV infection. J Med Virol2020; 10.1002. 8.Karmen-TuohySCarlucciPMZacharioudakisIMZervouFNRebickGKleinEet al.Outcomes among" exact="HIV-positive" post="patients hospitalized with COVID-19. medRxiv2020; [Online ahead of print]."/>
  <result pre="9.GervasoniCMeravigliaPRivaAGiacomelliAOreniLMinisciDet al.Clinical features and outcomes of HIV patients with coronavirus" exact="disease" post="2019. Clin Infect Dis2020; ciaa579doi:10.1093/cid/ciaa579.32407467 10.VizcarraPPerez-EliasMJQueredaCMorenoAVivancosMJDrondaFet al.Description of COVID-19"/>
  <result pre="Med2020; 9:E1733.32512688 13.What to Know About HIV and COVID-19. Coronavirus" exact="Disease" post="2019 (COVID-19). Centers for Disease Control and Prevention. Content"/>
  <result pre="About HIV and COVID-19. Coronavirus Disease 2019 (COVID-19). Centers for" exact="Disease" post="Control and Prevention. Content source: National Center for Immunization"/>
  <result pre="Control and Prevention. Content source: National Center for Immunization and" exact="Respiratory" post="Diseases (NCIRD), Division of Viral Diseases. [Accesssed 26 June"/>
  <result pre="and Prevention. Content source: National Center for Immunization and Respiratory" exact="Diseases" post="(NCIRD), Division of Viral Diseases. [Accesssed 26 June 2020]"/>
  <result pre="National Center for Immunization and Respiratory Diseases (NCIRD), Division of" exact="Viral" post="Diseases. [Accesssed 26 June 2020] 14.COVID-19 &amp;amp; HIV. BHIVA,"/>
  <result pre="active antiretroviral therapy in the prevention and treatment of severe" exact="acute" post="respiratory syndrome. Clin Infect Dis2004; 38:10301032.15034838 18.JockuschSTaoCLiXAndersonTKChienMKumarSet al.Triphosphates of"/>
  <result pre="antiretroviral therapy in the prevention and treatment of severe acute" exact="respiratory" post="syndrome. Clin Infect Dis2004; 38:10301032.15034838 18.JockuschSTaoCLiXAndersonTKChienMKumarSet al.Triphosphates of the"/>
  <result pre="living with HIV at higher risk for developing severe coronavirus" exact="disease" post="2019 (COVID-19)?. AIDS Patient Care STDS2020; 34:247248.32407127 21.World Health"/>
  <result pre="(COVID-19)?. AIDS Patient Care STDS2020; 34:247248.32407127 21.World Health Organization. Coronavirus" exact="disease" post="(COVID-19) Pandemic. Coronavirus. Symptoms. In: https://www.who.int/health-topics/coronavirus#tab=tab_3. 22.National Center for"/>
  <result pre="Pandemic. Coronavirus. Symptoms. In: https://www.who.int/health-topics/coronavirus#tab=tab_3. 22.National Center for Immunization and" exact="Respiratory" post="Diseases (NCIRD) DoVD. Symptoms of Coronavirus. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html."/>
  <result pre="Coronavirus. Symptoms. In: https://www.who.int/health-topics/coronavirus#tab=tab_3. 22.National Center for Immunization and Respiratory" exact="Diseases" post="(NCIRD) DoVD. Symptoms of Coronavirus. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. [Updated"/>
  <result pre="2020]. 23.ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="25.World Health Organization. Global surveillance for COVID-19 caused by human" exact="infection" post="with COVID-19 virus: interim guidance. In: https://www.who.int/publications/i/item/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance. [Accesssed 9"/>
  <result pre="with community-acquired pneumonia. An official clinical practice guideline of the" exact="American" post="Thoracic Society and Infectious Diseases Society of America. Am"/>
  <result pre="community-acquired pneumonia. An official clinical practice guideline of the American" exact="Thoracic" post="Society and Infectious Diseases Society of America. Am J"/>
  <result pre="official clinical practice guideline of the American Thoracic Society and" exact="Infectious" post="Diseases Society of America. Am J Respir Crit Care"/>
  <result pre="clinical practice guideline of the American Thoracic Society and Infectious" exact="Diseases" post="Society of America. Am J Respir Crit Care Med2019;"/>
  <result pre="as a clinical presentation of mild-to-moderate forms of the coronavirus" exact="disease" post="(COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol2020; 277:22512261.32253535"/>
  <result pre="options. Clin Immunol2020; 215:108448.32353634 33.GaoZXuYSunCWangXGuoYQiuSet al.A systematic review of asymptomatic" exact="infections" post="with COVID-19. J Microbiol Immunol Infect2020; 10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001."/>
 </snippets>
</snippetsTree>
